Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Nov 6;27(11):1874-1877.
doi: 10.1016/j.ymthe.2019.09.022. Epub 2019 Oct 2.

Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?

Dmitriy Zamarin  1
Affiliations
Comment

Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum?

Dmitriy Zamarin. Mol Ther. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intratumoral Immunomodulation with Engineered Viruses: Context and Ligand Matters (A) Ballesteros-Briones et al. have demonstrated that PD-L1 expressed from SFV results in superior therapeutic efficacy when compared to PD-L1 expressed from AAV. (B) Expression of sPD-1/CD137L from a single adenoviral vector is superior to the combination of adenoviral vectors expressing either ligand alone.
See this image and copyright information in PMC

Comment on

References

    1. Zhang Y., Zhang H., Wei M., Mou T., Shi T., Ma Y., Cai X., Li Y., Dong J., Wei J. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC. Mol. Ther. 2019;27:1963–1973. this issue. - PMC - PubMed
    1. Ballesteros-Briones M.C., Martisova E., Casales E., Silva-Pilipich N., Buñuales M., Galindo J., Mancheño U., Gorraiz M., Lasarte J.J., Kochan G. Short-term local expression of a PD-L1 blocking antibody from a self-replicating RNA vector induces potent antitumor responses. Mol. Ther. 2019;27:1892–1905. this issue. - PMC - PubMed
    1. Callahan M.K., Postow M.A., Wolchok J.D. Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016;44:1069–1078. - PubMed
    1. Segal N.H., Logan T.F., Hodi F.S., McDermott D., Melero I., Hamid O., Schmidt H., Robert C., Chiarion-Sileni V., Ascierto P.A. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin. Cancer Res. 2017;23:1929–1936. - PubMed
    1. Pierce R.H., Campbell J.S., Pai S.I., Brody J.D., Kohrt H.E. In-situ tumor vaccination: Bringing the fight to the tumor. Hum. Vaccin. Immunother. 2015;11:1901–1909. - PMC - PubMed

Publication types

Substances